World Library  

Add to Book Shelf
Flag as Inappropriate
Email this Book

Plos One : Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials, Volume 7

By Bayer, Antony

Click here to view

Book Id: WPLBN0003937078
Format Type: PDF eBook :
File Size:
Reproduction Date: 2015

Title: Plos One : Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials, Volume 7  
Author: Bayer, Antony
Volume: Volume 7
Language: English
Subject: Journals, Science, Medical Science
Collections: Periodicals: Journal and Magazine Collection (Contemporary)
Publication Date:
Publisher: Plos


APA MLA Chicago

Bayer, A. (n.d.). Plos One : Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials, Volume 7. Retrieved from

Description : The tau and amyloid pathobiological processes underlying Alzheimer disease (AD) progresses slowly over periods of decades before clinical manifestation as mild cognitive impairment (MCI), then more rapidly to dementia, and eventually to end-stage organ failure. The failure of clinical trials of candidate disease modifying therapies to slow disease progression in patients already diagnosed with early AD has led to increased interest in exploring the possibility of early intervention and prevention trials, targeting MCI and cognitively healthy (HC) populations. Here, we stratify MCI individuals based on cerebrospinal fluid (CSF) biomarkers and structural atrophy risk factors for the disease. We also stratify HC individuals into risk groups on the basis of CSF biomarkers for the two hallmark AD pathologies. Results show that the broad category of MCI can be decomposed into subsets of individuals with significantly different average regional atrophy rates. By thus selectively identifying individuals, combinations of these biomarkers and risk factors could enable significant reductions in sample size requirements for clinical trials of investigational AD-modifying therapies, and provide stratification mechanisms to more finely assess response to therapy. Power is sufficiently high that detecting efficacy in MCI cohorts should not be a limiting factor in AD therapeutics research. In contrast, we show that sample size estimates for clinical trials aimed at the preclinical stage of the disorder (HCs with evidence of AD pathology) are prohibitively large. Longer natural history studies are needed to inform design of trials aimed at the presymptomatic stage.


Click To View

Additional Books

  • Plos One : the C. Elegansrab Family ; Id... (by )
  • Plos One : the Pharmacokinetic-pharmacod... (by )
  • Plos One : Liver-targeting of Interferon... (by )
  • Plos One : Phenotypes of Allo- and Autoi... (by )
  • Plos One : Crystal Structure, Saxs and K... (by )
  • Plos One : Comparison of Long-term Survi... (by )
  • Plos One : Peer Support and Exclusive Br... (by )
  • Plos One : Next Generation Sequencing to... (by )
  • Plos One : Preconditioning Triggered by ... (by )
  • Plos One : Y-chromosome Diversity in Mod... (by )
  • Plos One : Inhibition of Cell Division I... (by )
  • Plos One : a Thermokinetic Approach to R... (by )
Scroll Left
Scroll Right


Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.